post-transplant lymphoproliferative disorder

Also found in: Wikipedia.

post-transplant lymphoproliferative disorder

A family of Epstein-Barr virus-associated lymphoid expansions with a range of histologies, from infectious mononucleosis-like lymphoid hyperplasia to monoclonal neoplasms, that may not be classifiable as specific types of non-Hodgkin lymphoma, even if typical genetic defects are present. Monoclonal post-transplant lymphoproliferative disorders (PTLDs) do not regress when immunosuppression is withdrawn. PTLD occurs in 1–10% of organ transplant recipients; most cases that occur in solid organ recipients are of host origin.

Post-transplant patients at risk for PTLD can be identified by detecting expression (as small mRNA) of the EBER-1 gene.

Malignant features may regress with reduced immunosuppression.
References in periodicals archive ?
Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience.
Identifying the patient at risk for post-transplant lymphoproliferative disorder.
Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, has received European Commission orphan drug designations for CMD-003 (baltaleucel-T) as a treatment for extranodal NK/T-cell lymphoma, nasal type, and post-transplant lymphoproliferative disorder.
Post-transplant lymphoproliferative disorder (PTLD) occurs in 1-10% of patients undergoing solid-organ transplantation and presents predominantly in the first year.
The virus can then reawaken and drive the development of B cell cancers like AIDS-associated B cell lymphoma and post-transplant lymphoproliferative disorder.
But while recovering from the transplant, a PET scan revealed she had developed post-transplant lymphoproliferative disorder (PTLD), a condition which can lead to cancer.
Post-transplant lymphoproliferative disorder (PTLD) can be attributed to an acute infection with EBV following transplantation.
A new Guideline detailing diagnosis, workup, and treatment options for Post-Transplant Lymphoproliferative Disorder (PTLD), as well as stronger recommendations for therapies in follicular lymphoma, topped the list of highlights in a presentation of the updated NCCN Guidelines([TM]) for Non-Hodgkin's Lymphomas (NHL).
Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide.
Belatacept carries an FDA-mandated warning for an increased risk of developing post-transplant lymphoproliferative disorder (PTLD), a type of cancer where white blood cells grow out of control after an organ transplant.
Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study.

Full browser ?